Drugs in the Pipeline, News
FDA Issues EUA to Baricitinib Plus Remdesivir for Hospitalized COVID-19 Patients
The EUA was granted based on data from the phase 3 ACTT-2 trial, which was conducted by the NIAID.
Your search for supplemental oxygen returned 15 results
Drugs in the Pipeline
Early Data Show Potential Benefit of Acalabrutinib in Severe COVID-19
Acalabrutinib, a Bruton tyrosine kinase (BTK) inhibitor, appears to reduce respiratory distress as well as the hyperinflammatory immune response associated with coronavirus disease 2019.
Drugs in the Pipeline
NIH Trial Evaluating Remdesivir Plus Baricitinib for COVID-19 Initiated
Baricitinib, a JAK inhibitor, is currently approved in the US for rheumatoid arthritis.
Drugs in the Pipeline, News
FDA Greenlights Study to Evaluate Opaganib in Patients With Moderate to Severe COVID-19
The FDA has approved the Investigational New Drug (IND) application for the phase 2a study of opaganib (RedHill Biopharma) in patients with confirmed moderate to severe SARS-CoV-2 infection.
Drugs in the Pipeline
NIH: Remdesivir Plus Interferon Beta-1a Being Evaluated for COVID-19
The placebo-controlled ACTT 3 trial will evaluate the efficacy and safety of remdesivir in combination with interferon beta-1a in more than 1000 hospitalized COVID-19 patients.
Drugs in the Pipeline
Trials Testing Convalescent Plasma for COVID-19 Expanded
Both randomized, placebo-controlled trials are expected to enroll approximately 1000 hospitalized patients.
Drugs in the Pipeline
Baricitinib Plus Remdesivir Cuts Time to Recovery for Hospitalized COVID-19 Patients
The ACTT-2 study began on May 8 and included more than 1000 patients.
Drugs in the Pipeline
Antiviral Merimepodib to Be Investigated in Phase 2 Trial for COVID-19
Following clearance of an Investigational New Drug Application by the Food and Drug Administration, ViralClear announced that a phase 2 study evaluating merimepodib oral solution for the treatment of coronavirus disease 2019 (COVID-19) will be initiated.
Drugs in the Pipeline
Mixed Results for Baricitinib in Trial of Hospitalized COVID-19 Patients
Findings showed that the trial did not meet statistical significance on the primary endpoint.
Drugs in the Pipeline
Lenzilumab Promising for Hospitalized Patients With COVID-19
Lenzilumab is an investigational anti-human granulocyte macrophage-colony stimulating factor monoclonal antibody.
